18.21USD+9.04%Mkt Cap: —P/E: —Last update: 2026-05-26
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule fo…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value483.51M USD
Revenue (TTM)63.26M USD
Gross Profit42.34M USD
Net Income (TTM)6.82M USD
Revenue/Share2.267 USD
Last Price18.21 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees78
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-7.38
EV/Revenue7.64
P/S—
P/B10.25
EPS (TTM)-0.86
EPS (Forward)—
52W Range
6.27099% of range18.34
52W High18.34 USD
52W Low6.270 USD
Profitability
Gross Margin66.92%
Oper. Margin-29.78%
EBITDA Margin-103.63%
Profit Margin10.77%
ROE13.66%
ROA3.67%
Growth
Revenue Growth6.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-65.78M USD
CapEx (TTM)—
FCF Margin-74.75%
FCF Yield—
Net Debt-12.16M USD
Net Debt/EBITDA0.19
Balance Sheet
Debt/Equity1.49
Current Ratio2.49
Quick Ratio2.20
Book Value/Sh1.590 USD
Cash/Share2.465 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield14.44%
Payout Ratio—
Ex-Div DateJun 14, 2024
Pay DateJun 30, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.56.68M
Float22.38M
Insiders0.00%
Institutions0.00%
Short Interest
Short Ratio0.0d
Shares Short1.04K
Short (prev mo.)298
Technical
SMA 5013.88 (+31.2%)
SMA 20010.36 (+75.7%)
Beta1.16
S&P 52W Chg28.31%
Avg Vol (30d)19.14K
Avg Vol (10d)27.57K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—